

# 2025 Current Fiscal Year Report: The President's Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board

Report Run Date: 05/23/2025 05:13:37 AM

<b>1. Department or Agency</b>		<b>2. Fiscal Year</b>	
Department of State		2025	
<b>3. Committee or Subcommittee</b>		<b>3b. GSA Committee No.</b>	
The President's Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board		76050	
<b>4. Is this New Fiscal Year?</b>	<b>5. Current Charter</b>	<b>6. Expected Renewal Date</b>	<b>7. Expected Term Date</b>
No	02/25/2025	02/25/2027	
<b>8a. Was Terminated During Fiscal Year?</b>	<b>8b. Specific Termination Authority</b>		<b>8c. Actual Term Date</b>
No	Public Law 92-463, Section 14		
<b>9. Agency Recommendation for Next Fiscal Year</b>	<b>10a. Legislation Req to Terminate?</b>	<b>10b. Legislation Pending?</b>	
Continue	Not Applicable	Not Applicable	
<b>11. Establishment Authority</b>	Agency Authority		
<b>12. Specific Establishment Authority</b>	<b>13. Effective Date</b>	<b>14. Committee Type</b>	<b>14c. Presidential?</b>
Secretary of State and Department of State (Section 2656 of Title 22 of the United States Code)	12/05/2010	Continuing	No
<b>15. Description of Committee</b> Other Committee			
<b>16a. Total Number of Reports</b>	No Reports for this Fiscal Year		
<b>17a. Open</b>	<b>17b. Closed</b>	<b>17c. Partially Closed</b>	<b>Other Activities</b>
0	0	0	0
<b>17d. Total</b> 0			

## Meetings and Dates

No Meetings

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$0.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$0.00	\$0.00
<b>18d. Total</b>	\$0.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.00	0.00

## 20a. How does the Committee accomplish its purpose?

The Board serves the U.S. Global AIDS Coordinator ("the Coordinator") in a solely advisory capacity concerning scientific, implementation, and policy issues related to the global response to HIV/AIDS. These issues will be of concern as they influence the priorities and direction of PEPFAR evaluation and research, the content of national and international strategies and implementation, and the role of PEPFAR in the

international discourse regarding appropriate and resourced responses. The committee accomplishes its purpose largely through the generation of recommendations.

**20b. How does the Committee balance its membership?**

The Board is composed of up to 50 members appointed by the Coordinator, representing non-U.S. Government personnel. All Board members are representative members. The membership is representative of the HIV/AIDS community, academia, international experts, partner government representatives, multilateral and bilateral agency representatives, foundations, advocates, and non-governmental organizations.

**20c. How frequent and relevant are the Committee Meetings?**

Original Estimated Number of Meetings per Year - 1 or 2 face-to-face meetings with teleconferences as needed. In order to keep committee meetings relevant and productive, working groups (subcommittees) have been formed that meet intermittently and on an ad-hoc basis. The ideas and advice generated by the working groups result in increased productivity and clearer recommendations produced by the whole committee during face-to-face meetings.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

The committee is necessary to keep PEPFAR programs at the forefront of scientific knowledge. The members of the committee have specific expertise which is relevant and crucial to PEPFAR in creating and implementing high-quality programs. The advice received by the Coordinator from the committee in the past fiscal year has

assisted PEPFAR by informing next steps on how to swiftly pivot programs to achieve greater impact in response to new HIV normative guidance from the World Health Organization and others.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

N/A

**21. Remarks**

This committee advises PEPFAR on science, implementation, and technical policy issues. Its function is best described as "Other" due to this broad scope. Further, this committee does not routinely produce formal reports, but does issue recommendations on policy decisions that are captured in the meeting minutes following each meeting. For a full meeting summary, including recommendations offered by the Board, please follow the link below where you may find past meeting minutes. Please see [www.state.gov/scientific-advisory-board-pepfar/](http://www.state.gov/scientific-advisory-board-pepfar/) It was determined during this fiscal year that the majority of the SAB members would be retired to bring in new perspectives and reform the SAB. 5 members of the SAB were retained and the rest were informed of the retirement on September 24 2024. New members will be onboarding in the coming fiscal year and are currently being contacted. The following subcommittees were retired as they were inactive in 2023 and 2024: (1) Finance and Economics Working Group; (2) HIV Prevention Continuum Working Group; and (3) HIV Recency Testing.

**Designated Federal Officer**

Emily Innis DFO

Committee Members	Start	End	Occupation	Member Designation
-------------------	-------	-----	------------	--------------------

		Associate Professor, Epidemiology, Mailman School of Public Health; Adjunct Professor, Public Health and Family Medicine, Nelson R. Mandela School of Medicine; Associate Scientific Director	
Abdool-Karim, Quarraisha	03/17/2017 09/24/2026		Representative Member
Adeyi, Olusoji	11/07/2024	Resilient Health Systems	Representative Member
Adzogenu, Edem	11/07/2024	AFROChampions	Representative Member
Barreira, Draurio	11/07/2024	Brazilian MOH	Representative Member
Bekker, Linda Gail	11/07/2024	Desmond Tutu Foundation	Representative Member
Bukusi, Elizabeth	11/07/2024	KEMRI	Representative Member
Castellanos, Erika	11/07/2024	GATE	Representative Member
Chalkidou, Kalipso	11/07/2024	WHO	Representative Member
Collins, Pamela	11/07/2024	JHU Bloomberg SPH	Representative Member
Doherty, Meg	11/07/2024	WHO	Representative Member
Geng, Elvin	11/07/2024	University of Washington, St Louis, USA	Representative Member
Imai-Eaton, Jeff	11/07/2024	Harvard University	Representative Member
Kabane, Sipho	11/07/2024	Council for Medical Schemes in South Africa	Representative Member
Kambugu, Andrew	11/07/2024	IDI, Makerere University	Representative Member
Kates, Jennifer	03/17/2017 09/24/2026	Vice President and Director of Global Health and HIV Policy	Representative Member
Khanyola, Judy	11/07/2024	UGHE, Rwanda	Representative Member
Magongo Namusoke,, Eleanor	11/07/2024	Uganda MoH	Representative Member
Maleche, Allan	11/07/2024	KELLIN	Representative Member
McClelland, Amanda	11/07/2024	Resolve	Representative Member

Millett, Greg	10/01/2021	09/24/2026	vice president and director of public policy	Representative Member
Mosepele, Mosepele	11/07/2024		University of Botswana	Representative Member
Njeru, Nkatha	11/07/2024		ACHAP	Representative Member
Phanuphak, Nittaya	11/07/2024		Institute of HIV Research and Innovation in Bangkok, Thailand	Representative Member
Pillay, Yogan	09/24/2024	09/24/2026	Gates Foundation	Special Government Employee (SGE) Member
Riako Anam, Florence	11/07/2024		GNP+	Representative Member
Sikazwe, Izukanji	11/07/2024		Centre for Infectious Disease Research in Zambia	Representative Member
Swindells, Susan	10/01/2021	09/24/2026	Physician	Representative Member
Van Renterghem, Henk	11/07/2024		UNAIDS	Representative Member
Walters, Ricardo	11/07/2024		Positive Vibes	Representative Member
Warren, Mitchell	03/17/2017	09/24/2026	Executive Director	Representative Member
Auerbach, Judy [Behavioral and Social Science Subcommittee]	04/01/2024		UCSF	Special Government Employee (SGE) Member
Celum, Connie [Behavioral and Social Science Subcommittee]	04/01/2024		University of Washington	Special Government Employee (SGE) Member
Cluver, Lucie [Behavioral and Social Science Subcommittee]	07/01/2024		University of Oxford	Special Government Employee (SGE) Member
Maxwell, Celia [Behavioral and Social Science Subcommittee]	04/01/2024		Howard University	Special Government Employee (SGE) Member
Mayer, Kenneth [Behavioral and Social Science Subcommittee]	04/01/2024		Harvard University	Special Government Employee (SGE) Member
Mushavi, Angela [Behavioral and Social Science Subcommittee]	07/01/2024		Ministry of Health, Zimbabwe	Special Government Employee (SGE) Member

Ngure, Kenneth [Behavioral and Social Science Subcommittee]	07/01/2024	University of Washington	Special Government Employee (SGE) Member
Adzogenu, Edem [Global Health Security Subcommittee]	03/04/2024	AfroChampions	Special Government Employee (SGE) Member
Bhandari, Neeta [Global Health Security Subcommittee]	03/04/2024	Gates Foundation	Special Government Employee (SGE) Member
Bliss, Katherine [Global Health Security Subcommittee]	03/04/2024	CSIS	Special Government Employee (SGE) Member
Carlson, Colin [Global Health Security Subcommittee]	03/04/2024	Georgetown	Special Government Employee (SGE) Member
Garcia, Patricia [Global Health Security Subcommittee]	03/04/2024	School of Public Health at Cayetano Heredia University	Special Government Employee (SGE) Member
Hersey, Sarah [Global Health Security Subcommittee]	03/04/2024	WHO Intelligence HUB	Special Government Employee (SGE) Member
Mabuchi, Shun [Global Health Security Subcommittee]	03/04/2024	Global Fund RSSH	Special Government Employee (SGE) Member
McClelland, Amanda [Global Health Security Subcommittee]	03/04/2024	Resolve To Save Lives	Special Government Employee (SGE) Member
Morhard, Ryan [Global Health Security Subcommittee]	03/04/2024	Takeda Pharmaceuticals	Special Government Employee (SGE) Member
Sawe, Fred [Global Health Security Subcommittee]	03/04/2024	KEMRI	Special Government Employee (SGE) Member
Tajudeen, Raji [Global Health Security Subcommittee]	03/04/2024	Africa CDC	Special Government Employee (SGE) Member
Wakaba Ale, Nelly [Global Health Security Subcommittee]	03/04/2024	Mastercard Foundation	Special Government Employee (SGE) Member

Abdool Karim, Quarraisha [Sustainability Advisory Group]	03/01/2024	CAPRISA & Columbia University	Special Government Employee (SGE) Member
Adeyi, Olusoji [Sustainability Advisory Group]	03/01/2024	World Bank, Director of Global Practice	Special Government Employee (SGE) Member
Ayepong, Irene [Sustainability Advisory Group]	03/01/2024	Ghana Health Services	Special Government Employee (SGE) Member
Bennett, Sara [Sustainability Advisory Group]	03/01/2024	JHU	Special Government Employee (SGE) Member
Berman, Peter [Sustainability Advisory Group]	03/01/2024	UBC	Special Government Employee (SGE) Member
Chaikidu, Kalipso [Sustainability Advisory Group]	03/01/2024	Global Fund	Special Government Employee (SGE) Member
Kates, Jennifer [Sustainability Advisory Group]	03/01/2024	KFF	Special Government Employee (SGE) Member
Pillay, Yogan [Sustainability Advisory Group]	03/01/2024	BMGF	Special Government Employee (SGE) Member
Sikazwe, Zuzu [Sustainability Advisory Group]	03/01/2024	CIDRZ	Special Government Employee (SGE) Member
Yamey, Gavin [Sustainability Advisory Group]	03/01/2024	Duke University	Special Government Employee (SGE) Member

**Number of Committee Members Listed: 59**

### **Narrative Description**

The Board serves the Global AIDS Coordinator (“the Coordinator”) in a solely advisory capacity concerning scientific, implementation, and policy issues related to the global response to HIV/AIDS. These issues are of ongoing concern and serve to maximize the impact of our investments in controlling the HIV epidemic and delivering on the promise of an AIDS-free generation.



**What are the most significant program outcomes associated with this committee?**

Checked if  
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input checked="" type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input type="checkbox"/>

**Outcome Comments**

N/A

**What are the cost savings associated with this committee?**

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input checked="" type="checkbox"/>

**Cost Savings Comments**

This is not the purpose of the committee and is difficult to quantify. However, recommendations have directly contributed to programmatic efficiencies that in turn extend the value of the PEPFAR dollar.

**What is the approximate Number of recommendations produced by this committee for the life of the committee?**

60

### **Number of Recommendations Comments**

Through the FY22 reporting period, the PEPFAR Scientific Advisory Board has issued 65 recommendations. FY22 recommendations focused on the technical considerations for the implementation of HIV recency testing for surveillance, new biomedical products for HIV prevention, implementation science, use of self-testing for PrEP, and HPV testing. Through the FY23 reporting period, the PEPFAR Scientific Advisory Board convened to discuss the role of the Board during the formation of the GHSD bureau, and to discuss updates in science related to PEPFAR programs. During the FY 2024 period, the five recommendations provided by the board covered issues such as inclusive HIV care for key populations, addressing stagnant funding and equity, monitoring Dolutegravir resistance, advancing long-acting treatments, behavioral science for improved outcomes, and sustainable health system integration.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

85%

### **% of Recommendations Fully Implemented Comments**

To date, approximately 85% of all recommendations have been fully implemented by the agency, and progress is being made to partially and fully implement additional recommendations.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

14%

### **% of Recommendations Partially Implemented Comments**

Based on the broad nature of many of the recommendations issued by the Board through the FY24 reporting period, roughly 14% of recommendations are most accurately described as partially implemented.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☒ No ☐ Not Applicable ☐

### **Agency Feedback Comments**

PEPFAR provides feedback at : <https://www.state.gov/scientific-advisory-board-pepfar/>

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

- |                                   |                                     |
|-----------------------------------|-------------------------------------|
| Reorganized Priorities            | <input checked="" type="checkbox"/> |
| Reallocated resources             | <input type="checkbox"/>            |
| Issued new regulation             | <input type="checkbox"/>            |
| Proposed legislation              | <input type="checkbox"/>            |
| Approved grants or other payments | <input type="checkbox"/>            |
| Other                             | <input type="checkbox"/>            |

**Action Comments**

N/A

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

N/A

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

- |                           |                                     |
|---------------------------|-------------------------------------|
| Contact DFO               | <input checked="" type="checkbox"/> |
| Online Agency Web Site    | <input checked="" type="checkbox"/> |
| Online Committee Web Site | <input checked="" type="checkbox"/> |
| Online GSA FACA Web Site  | <input checked="" type="checkbox"/> |
| Publications              | <input type="checkbox"/>            |
| Other                     | <input type="checkbox"/>            |

**Access Comments**

N/A